Back

Veru advances sabizabulin after 18.2 nM activity against daraxonrasib-resistant cancer

Verifying
  • Veru plans to advance oral sabizabulin for daraxonrasib-resistant metastatic pancreatic cancer.
  • 18.2 nM was sabizabulin’s IC50 in a resistant human pancreatic cancer cell line.
  • Veru plans an FDA preIND meeting in the fourth quarter of calendar 2026.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.